1. A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors - Full Text View - ClinicalTrials.gov.” Accessed: Jul. 17, 2023. [Online]. Available: 〈https://classic.clinicaltrials.gov/ct2/show/NCT04278144〉.
2. A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors - Full Text View - ClinicalTrials.gov.” Accessed: Jul. 17, 2023. [Online]. Available: https://classic.clinicaltrials.gov/ct2/show/NCT03595059.
3. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize;Adams;Nat. Commun.,2016
4. ADC Drug Map | ADC Review.” Accessed: May 05, 2023. [Online]. Available: 〈https://www.adcreview.com/adc-drugmap/〉.
5. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity;Ajgal;Cancer Radio.,2017